{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=CHEK2+Gene+Mutation",
    "query": {
      "condition": "CHEK2 Gene Mutation"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 8,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T04:51:38.818Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03377556",
      "title": "Lung-MAP: Talazoparib in Treating Patients With HRRD Positive Recurrent Stage IV Squamous Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ATM Gene Mutation",
        "ATR Gene Mutation",
        "BARD1 Gene Mutation",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "BRIP1 Gene Mutation",
        "CHEK1 Gene Mutation",
        "CHEK2 Gene Mutation",
        "FANCA Gene Mutation",
        "FANCC Gene Mutation",
        "FANCD2 Gene Mutation",
        "FANCF Gene Mutation",
        "FANCM Gene Mutation",
        "NBN Gene Mutation",
        "PALB2 Gene Mutation",
        "RAD51 Gene Mutation",
        "RAD51B Gene Mutation",
        "RAD54L Gene Mutation",
        "Recurrent Squamous Cell Lung Carcinoma",
        "RPA1 Gene Mutation",
        "Stage IV Squamous Cell Lung Carcinoma AJCC v7"
      ],
      "interventions": [
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Talazoparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 51,
      "start_date": "2017-03-03",
      "completion_date": "2021-04-16",
      "has_results": true,
      "last_update_posted_date": "2021-06-23",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 1151,
      "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 713 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03377556"
    },
    {
      "nct_id": "NCT06177171",
      "title": "Olaparib and ASTX727 in BRCA1/2- and Homologous Recombination Deficient (HRD)-Mutated Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "BRCA2 Mutation",
        "BRCA Mutation",
        "PALB2 Gene Mutation",
        "Checkpoint Kinase 2 Gene Mutation",
        "ATM Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        },
        {
          "name": "ASTX727",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pamela Munster",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2024-02-07",
      "completion_date": "2028-01-31",
      "has_results": false,
      "last_update_posted_date": "2026-02-02",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06177171"
    },
    {
      "nct_id": "NCT03344965",
      "title": "Olaparib In Metastatic Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Breast Cancer",
        "Invasive Breast Cancer",
        "Somatic Mutation Breast Cancer (BRCA1)",
        "Somatic Mutation Breast Cancer (BRCA2)",
        "CHEK2 Gene Mutation",
        "ATM Gene Mutation",
        "PALB2 Gene Mutation",
        "RAD51 Gene Mutation",
        "BRIP1 Gene Mutation",
        "NBN Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 114,
      "start_date": "2018-04-01",
      "completion_date": "2026-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-05",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 20,
      "location_summary": "Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 15 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03344965"
    },
    {
      "nct_id": "NCT02401347",
      "title": "Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Breast Cancer",
        "HER2/Neu Negative",
        "Triple-Negative Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Talazoparib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melinda Telli",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2015-08",
      "completion_date": "2022-12",
      "has_results": true,
      "last_update_posted_date": "2023-02-21",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 1,
      "location_summary": "Stanford, California",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02401347"
    },
    {
      "nct_id": "NCT04030559",
      "title": "Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "ATM Gene Mutation",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "BRIP1 Gene Mutation",
        "CDK12 Gene Mutation",
        "CHEK1 Gene Mutation",
        "CHEK2 Gene Mutation",
        "DNA Damage Response Gene Mutation",
        "DNA Repair Gene Mutation",
        "FANCA Gene Mutation",
        "FANCD2 Gene Mutation",
        "FANCL Gene Mutation",
        "GEN1 Gene Mutation",
        "NBN Gene Mutation",
        "Prostate Carcinoma",
        "RAD51 Gene Mutation",
        "RAD51C Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Niraparib",
          "type": "DRUG"
        },
        {
          "name": "Niraparib Tosylate Monohydrate",
          "type": "DRUG"
        },
        {
          "name": "Radical Prostatectomy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "University of California, Davis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 11,
      "start_date": "2020-02-25",
      "completion_date": "2025-11-07",
      "has_results": true,
      "last_update_posted_date": "2026-05-14",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04030559"
    },
    {
      "nct_id": "NCT07499999",
      "title": "Randomized Double-Blind Phase II Trial of Baby Exemestane Versus Baby Tamoxifen in Post-Menopausal Women at High Risk for Breast Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Cancer",
        "Ductal Carcinoma",
        "Estrogen-receptor-positive Breast Cancer",
        "Atypical Lobular Hyperplasia",
        "BRCA2 Mutation",
        "CHEK2 Gene Mutation",
        "Ataxia Telangiectasia Mutated Gene Mutation"
      ],
      "interventions": [
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Dana-Farber Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 140,
      "start_date": "2026-09-09",
      "completion_date": "2028-08-31",
      "has_results": false,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 2,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07499999"
    },
    {
      "nct_id": "NCT05787587",
      "title": "A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced or Metastatic Solid Tumors",
        "Breast Cancer",
        "Ovarian Cancer",
        "Prostate Cancer",
        "Endometrial Cancer",
        "Colorectal Cancer",
        "Head and Neck Cancers",
        "Extensive Stage Small Cell Lung Cancer (ES-SCLC)",
        "NSCLC"
      ],
      "interventions": [
        {
          "name": "IDE-161",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IDEAYA Biosciences",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2023-04-18",
      "completion_date": "2027-05",
      "has_results": false,
      "last_update_posted_date": "2026-02-09",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 27,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Newport Beach, California + 22 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05787587"
    },
    {
      "nct_id": "NCT05420064",
      "title": "An Intervention to Increase Genetic Testing in Families Who May Share a Gene Mutation Related to Cancer Risk and An Intervention to Help Patients and Their Primary Care Providers Stay Up-to-date About Uncertain Genetic Test Results",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "BRCA1 Mutation",
        "POLD1 Gene Mutation",
        "CDKN2A Mutation",
        "BRCA2 Mutation",
        "POLE Gene Mutation",
        "APC Gene Mutation",
        "ATM Gene Mutation",
        "MLH1 Gene Mutation",
        "BARD1 Gene Mutation",
        "MSH2 Gene Mutation",
        "BRIP1 Gene Mutation",
        "MSH6 Gene Mutation",
        "CHEK2 Gene Mutation",
        "PMS2 Gene Mutation",
        "PALB2 Gene Mutation",
        "EPCAM Gene Mutation",
        "RAD51C Gene Mutation",
        "BMPR1A Gene Mutation",
        "RAD51D Gene Mutation",
        "SMAD4",
        "PTEN Gene Mutation",
        "GREM1"
      ],
      "interventions": [
        {
          "name": "Intervention Arm At-risk Relative/ARR Contacts",
          "type": "BEHAVIORAL"
        },
        {
          "name": "MyGene Portal",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard of Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "25 Years and older"
      },
      "enrollment_count": 1000,
      "start_date": "2022-12-01",
      "completion_date": "2026-11-30",
      "has_results": false,
      "last_update_posted_date": "2025-11-12",
      "last_synced_at": "2026-05-22T04:51:38.818Z",
      "location_count": 8,
      "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more",
      "locations": [
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        },
        {
          "city": "Harrison",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05420064"
    }
  ]
}